BioRock Ventures Name

BioRock Ventures is an investment fund that specializes in venture capital investments. The firm invests in life sciences and biopharmaceutical startups developing treatments for serious medical diseases.

5 past transactions

Celldom

Venture Round in 2021
Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company’s TrapTx Analyzer System uniquely integrates both phenotypic and genomic data at massive scale (up to tens of thousands of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology.

Octagon Therapeutics

Series A in 2021
Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing antibiotics for multi-drug resistant infections, Octagon has demonstrated effectiveness against the most critical pathogens as identified by the WHO. Octagon World Headquarters is based in the Pagliuca Life Lab directly adjacent to Harvard campus. This state-of-the-art facility has allowed Octagon to accelerate the development of our vital medicines with minimal overhead and equipment costs. Octagon’s management team includes highly skilled scientists, clinicians, and entrepreneurs with decades of research experience and deep expertise in drug development. The scientific team is growing and continues to add top research talent.

Primmune Therapeutics

Series A in 2020
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.

Primmune Therapeutics

Seed Round in 2020
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.

AN2 Therapeutics

Series A in 2019
AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.